Bluebird bio Inc (NASDAQ:BLUE) finished Friday with an addition of $0.02 to close at $3.04, an upside of 0.66 percent. An average of 2,420,360 shares of common stock have been traded in the last five days. The last 20 days have seen an average of 3,300,630 shares traded, while the 50-day average volume stands at 3,901,982.
BLUE stock has decreased by -18.72% in the last month. The company shares reached their 1-month lowest point of $2.92 on 09/25/23. With the stock rallying to its 52-week high on 01/13/23, shares of the company touched a low of $2.78 and a high of $8.58 in 52 weeks. It has reached a new high 6 times so far this year and lost -56.07% or -$3.88 in price. In spite of this, the price is down -64.57% from the 52-week high.
Insider Transactions
BLUE stock investors should be aware that Bluebird bio Inc (BLUE) stock had its last reported insider trading activity 25 days ago on Sep 05. In this transaction, the insider spent $3,493. President and CEO, Obenshain Andrew, disposed of 16,929 shares at a price of $3.54 on Aug 10. The insider now owns more than $59,956 worth of shares. Prior to that, Klima Thomas J went on to Sale 4,130 shares at $3.50 each on Jun 02. An amount of $14,451 was transacted.
Valuation Metrics
Bluebird bio Inc (BLUE) stock’s beta is 0.94. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 34.59, the price-to-book (PB) ratio at 1.12.
Financial Health
The quick ratio of Bluebird bio Inc for the three months ended June 29 was 2.03, and the current ratio was 2.13, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.83 and a total debt to equity ratio of 1.06 for the quarter ending June 29. Its gross profit as reported stood at -$6.48 million compared to revenue of $3.6 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$72.91 million in the quarter, while revenues of $21.24 million were shrunk -37.35%. The analyst consensus anticipated Bluebird bio Inc’s latest quarter earnings to come in at -$0.72 per share, but it turned out to be -$0.67, a 6.90% surprise. For the quarter, EBITDA amounted to -$84.33 million. Shareholders own equity worth $106.95 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Bluebird bio Inc (BLUE) price momentum. RSI 9-day as of the close on 29 September was 31.56%, suggesting the stock is Neutral, with historical volatility in this time frame at 31.24%.
As of today, BLUE’s price is $3.05 unch or $unch from its 5-day moving average. BLUE is currently trading -19.36% lower than its 20-day SMA and -30.11% lower than its 100-day SMA. However, the stock’s current price level is -13.39% below the SMA50 and -62.33% below the SMA200.
The stochastic %K and %D were 16.78% and 17.26%, respectively, and the average true range (ATR) was 0.19. With the 14-day stochastic at 16.78% and the average true range at 0.20, the RSI (14) stands at 36.09%. The stock has reached -0.05 on the 9-day MACD Oscillator while the 14-day reading was at -0.14.
Analyst Ratings
HSBC Securities launched coverage on Bluebird bio Inc (NASDAQ: BLUE) in its analyst report released on September 06, 2023. The firm assigned the stock a Buy rating. The consensus rating for Bluebird bio Inc (BLUE) among analysts is Hold. According to current brokerage recommendations, 2 brokerage firms advise that investors sell BLUE, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 3 others rate it as a “buy”.
What is BLUE’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $11.00, with a median target of $7.50. Taking a look at these predictions, the average price target given by analysts for Bluebird bio Inc (BLUE) stock is $7.10.
